BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 3399222)

  • 21. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
    Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
    J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V; Nayer PD; Bouckaert A; Beckers C
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
    Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
    World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
    Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
    An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
    [No Abstract]   [Full Text] [Related]  

  • 29. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
    Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
    Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
    Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
    Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
    Giovanella L; Ceriani L; Ghelfo A; Keller F
    Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
    van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
    Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
    Gómez Camarero P; Martínez Brocca MA; Rodríguez Rodríguez JR; Navarro González E; Tirado Hospital JL; González Duarte D; Vázquez Albertino R; Astorga Jimenez R
    Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the relationship between chosen factors and results of whole body scintigraphy with 131I in patients with differentiated thyroid cancers].
    Mielcarek W; Dziuk E; Konieczna M; Kowalczyk A; Siekierzyński M
    Wiad Lek; 2001; 54 Suppl 1():363-7. PubMed ID: 12182050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children.
    Antonelli A; Miccoli P; Fallahi P; Ferrari SM; Grosso M; Boni G; Berti P
    Surgery; 2006 Dec; 140(6):1035-41; discussion 1041-2. PubMed ID: 17188154
    [No Abstract]   [Full Text] [Related]  

  • 37. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma.
    Grant S; Luttrell B; Reeve T; Wiseman J; Wilmshurst E; Stiel J; Donohoe D; Cooper R; Bridgman M
    Cancer; 1984 Oct; 54(8):1625-8. PubMed ID: 6478402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.